Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation

Neil E. Crittenden, Laura A. Buchanan, Christina M. Pinkston, Barbra Cave, Ashutosh Barve, Luis Marsano, Craig James McClain, Christopher M. Jones, Michael R. Marvin, Eric G. Davis, Candice B. Kuns‐Adkins, Roberto Gedaly, Guy Brock, Malay B. Shah, Jens Rosenau, Matthew C. Cave – 25 February 2016 – Although combination simeprevir (SIM) plus sofosbuvir (SOF) is an approved regimen for genotype 1 chronic hepatitis C virus (HCV), data regarding its safety and efficacy in liver transplant recipients remain limited.

Subscribe to